The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data.
The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data.
复制标题
Ezrin 免疫表达在骨肉瘤中的预后作用：已发表数据的荟萃分析
DOI：
10.1371/journal.pone.0064513
复制
发表时间：
2013
期刊：
影响因子：
3.7
通讯作者：
Shen Z
中科院分区：
文献类型：
--
作者：
Li H;Min D;Zhao H;Wang Z;Qi W;Zheng S;Tang L;He A;Sun Y;Yao Y;Shen Z
埃兹蛋白免疫表达和骨肉瘤预后的意义仍存在争议。目的是为骨肉瘤患者的埃兹蛋白免疫表达和预后特征提供荟萃分析。在MEDLINE、EMBASE和Web of Knowledge上详细检索了英文发表的相关原创文章；还评估了纳入研究的方法学质量。两名评审员独立提取数据。汇总研究并计算总结风险比 (HR) 和比值比 (OR) 以及相应的置信区间 (CI)。对来自 5 项符合条件的研究的 318 名患者进行了最终分析。埃兹蛋白免疫组织化学染色的组合HR表明，阳性免疫表达对骨肉瘤患者的总生存有不利影响（4项研究中n = 223；HR = 4.79；95% CI：1.50–15.30；P = 0.008），但对无事件生存没有不利影响（4项研究中n = 202） 3 项研究；HR = 1.59；95% CI：0.61–4.15；P = 0.0.342）。 ezrin免疫组织化学染色的组合OR表明，阳性免疫表达与复发相关（2项研究中n = 134；OR = 3.79；95% CI：1.49–9.64；P = 0.005），但与血清ALP水平无关（2项研究中n = 160； OR = 2.16；95% CI：0.09–52.50；P = 0.637）和新辅助化疗的组织学反应（4项研究中n = 260；OR = 0.87；95% CI：0.37–2.03；P = 0.740）。这项荟萃分析的结果表明，埃兹蛋白阳性免疫表达导致骨肉瘤患者复发风险更高，生存率更差。需要进行大型前瞻性研究来提供可靠的数据来研究埃兹蛋白的精确预后意义。
The significance of ezrin immunoexpression and prognosis for osteosarcoma is still controversial. The aim was to provide a meta-analysis for ezrin immunoexpression and prognostic features of osteosarcoma patients. A detailed search was made in MEDLINE, EMBASE and the Web of Knowledge for relevant original articles published in English; methodological quality of the included studies was also assessed. Two reviewers extracted data independently. Studies were pooled and summary hazard ratios (HRs) and odds ratio (ORs) with corresponding confidence intervals (CIs) were calculated. Final analysis of 318 patients from 5 eligible studies was performed. Combined HR of ezrin immunohistochemical staining suggested that positive immunoexpression had an unfavorable impact on osteosarcoma patients' overall survival (n = 223 in 4 studies; HR = 4.79; 95% CI: 1.50–15.30; P = 0.008) but not on event-free survival (n = 202 in 3 studies; HR = 1.59; 95% CI: 0.61–4.15; P = 0. 0.342). Combined OR of ezrin immunohistochemical staining indicated that positive immunoexpression was associated with recurrence (n = 134 in 2 studies; OR = 3.79; 95% CI: 1.49–9.64; P = 0.005) but not with serum ALP level (n = 160 in 2 studies; OR = 2.16; 95% CI: 0.09–52.50; P = 0.637) and histological response to neoadjuvant chemotherapy(n = 260 in 4 studies; OR = 0.87; 95% CI: 0.37–2.03; P = 0.740). The results of this meta-analysis suggest that ezrin positive immunoexpression confers a higher risk of recurrence and a worse survival in osteosarcoma patients. Large prospective studies are needed to provide solid data to investigate the precise prognostic significance of ezrin.
登录
查看更多内容
DOI：
10.1186/bcr1006
发表时间：
2005
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Elliott BE;Meens JA;SenGupta SK;Louvard D;Arpin M
通讯作者：
Arpin M
影响因子：
3.7
作者：
Picci P
通讯作者：
Picci P
影响因子：
5
作者：
Bax, Leon;Ikeda, Noriaki;Moons, Karel G. M.
通讯作者：
Moons, Karel G. M.
影响因子：
4.6
作者：
Kim, Chan;Shin, Eunah;Rha, Sun Young
通讯作者：
Rha, Sun Young
影响因子：
2.8
作者：
Park, Hye-Rim;Jung, Woon Won;Park, Yong-Koo
通讯作者：
Park, Yong-Koo